Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 24

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Basal cell carcinoma

Recruiting

Testing bifikafusp alfa and onfekafusp alfa injections in patients with locally advanced basal cell carcinoma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bifikafusp Alfa
  • Sponsor:Philogen S.p.A.

Colorectal cancer

Recruiting

Study of Recovery After Surgery for Colorectal Cancer Using Lidocaine and Ropivacaine in Patients Undergoing Laparoscopic Colorectal Cancer Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Celecoxib
  • Sponsor:Centre Hospitalier Universitaire Amiens Picardie

Endometrial cancer+6

Recruiting

A Study Testing BNT329 Safety and Effectiveness in Patients With Advanced Solid Tumors That Express the CA19-9 Tumor Marker

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:BioNTech SE

Adenocarcinoma pancreas+1

Recruiting

A study testing ASP3082 in patients with advanced or spreading non-small cell lung cancer and pancreatic ductal adenocarcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Institut Gustave Roussy

Adenocarcinoma pancreas

Recruiting

A Study of Olaparib Maintenance Treatment for Patients with Metastatic Pancreatic Cancer That Responded to First-Line Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:Universita Degli Studi Di Verona

Myelofibrosis

Recruiting

A Study of Pacritinib for Reducing Bone Marrow Scarring in Patients with Myelofibrosis Who Have Low Platelet Counts

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pacritinib
  • Sponsor:Grupo Espanol De Enfermedades Mieloproliferativas Cronicas Ph

Squamous cell carcinoma of head and neck

Recruiting

Study of nivolumab and ipilimumab immunotherapy for organ preservation in patients with advanced head and neck squamous cell carcinoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Transitional cell carcinoma metastatic

Recruiting

Study of Izalontamab Brengitecan Compared to Platinum-Based Chemotherapy for Patients with Metastatic Urothelial Cancer After Immunotherapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Acute myeloid leukaemia

Recruiting

Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Syndax Pharmaceuticals Inc.

Ovarian cancer

Recruiting

A Study of Carboplatin Given Directly into the Abdomen After Surgery in Elderly and Frail Patients with Ovarian Cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:65+ years
  • Substances:Carboplatin
  • Sponsor:Odense University Hospital

Breast cancer+3

Recruiting

A study testing zanidatamab combined with chemotherapy before surgery in patients with HER2-positive breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Jazz Pharmaceuticals Ireland Limited

Chronic lymphocytic leukaemia+2

Recruiting

A Study of Zanubrutinib for Patients with Anti-MAG Antibody Neuropathy Associated with Blood Disorders or Abnormal Protein in the Blood

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Zanubrutinib
  • Sponsor:Azienda Ospedaliera di Padova

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.